Drugs / Crinecerfont
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | CRENESSITY | — | 2024-12-13 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT07536269 | Apr 2026 → Mar 2028 expected | congenital adrenal hyperplasia | Neurocrine Biosciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07187375 | Sep 2025 → Sep 2029 expected | congenital adrenal hyperplasia | Neurocrine Biosciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04045145 | Dec 2019 → Jul 2021 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03525886 | Apr 2018 → Apr 2020 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT01034995 | Feb 2010 → Mar 2011 | major depressive disorder | Sanofi | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04806451 | Jun 2021 → Mar 2023 overdue | congenital adrenal hyperplasia | Neurocrine Biosciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04490915 | Dec 2020 → Jul 2023 overdue | congenital adrenal hyperplasia | Neurocrine Biosciences | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Crinecerfont | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07536269 ↗ |
| Known as | 06-RORI | ChEMBL registry synonym — accepted as the source's own label CHEMBL291657 ↗ |
| Known as | Crenessity | ChEMBL registry synonym — accepted as the source's own label CHEMBL291657 ↗ |
| Known as | NBI-74788 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525886 ↗ |
| Known as | SSR125543 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01034995 ↗ |
| Action | Inhibit | “Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist” PMID 37216921 ↗ Oct 20231“Corticotropin releasing factor receptor 1 antagonist” CHEMBL291657 ↗ |
| Modality | Small molecule | — CHEMBL291657 ↗ |
| Route | Oral | “Route of administration: oral” NCT01034995 ↗ |
| Target | CRHR1 | “Corticotropin releasing factor receptor 1 antagonist” CHEMBL291657 ↗ |